相关实验视频
Updated: Feb 4, 2026

An Aptamer-based Sensor for Unchelated GadoliniumIII
Published on: January 9, 2017
这是一种新的选方法,用于选抗超血性药物,该方法结合了阿普他默传感器阵列,外核酶III-DNA步行器和线性差异分析
Shiquan Zheng1, Jiale Ke1, Hanren Chen1
1NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
一种新的基于细胞的查方法,ASA-Exo III-DW-LDA,准确地检测尿酸 (UA) 尿酸降低药物的开发. 这种敏感且具有成本效益的方法可以识别像kaempferol这样有前途的候选药物.
科学领域:
- 生物化学 生物化学
- 分析化学 分析化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 降低尿酸 (UA) 的药物开发受到缺乏基于细胞的查方法的阻碍.
- 尿酸降低药物向诸如痛风和高尿血症等疾病.
研究的目的:
- 开发一种基于细胞的新,敏感和经济高效的查方法,用于发现尿酸降低药物.
- 为了验证该方法在识别潜在的酸盐降低化合物的有效性.
主要方法:
- 配合Aptamer传感器阵列 (ASA) 和由外核酶III (Exo III) 驱动的3D DNA步行器 (DW) 进行UA检测.
- 线性差异分析 (LDA) 来区分UA与类似的化合物,如丁 (Xan).
- 使用皮尔森相关性对抗URAT1抑制剂 (14C放射性标签) 的验证 (lesinurad,博马龙).
主要成果:
- 通过ASA-Exo III-DW-LDA方法实现了皮科莫拉UA检测灵敏度.
- 与已知的放射性方法有很强的相关性 (莱西努拉德的r=0.9880 ,博马龙的r=0.9777) .
- 凯姆菲罗尔被确定为具有低IC50 (18.96μM) 和低毒性的有前途的URAT1抑制剂.
结论:
- 开发的ASA-Exo III-DW-LDA方法是一种敏感,具有成本效益和安全的策略,用于例行尿酸降低药物查.
- 这种新的方法有助于在标准实验室中有效识别潜在的尿酸降低药物候选者.
- 根据体外和体内生物评估,珀醇显示出作为酸盐降低剂的显著潜力.
相关概念视频
Stereotypes, Prejudice, and Discrimination
Therapeutic Drug Monitoring: Drug Analysis Methods
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Methods of Documentation III: PIE
Generalization, Discrimination, and Extinction
Generalization occurs when a behavior reinforced in one context is performed in similar situations. For instance, a student who studies diligently for calculus and receives excellent grades might apply the same study habits to psychology and history, expecting similar results. Generalization shows how learning in one setting can influence behavior in...

